Keysight Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Keysight Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.38B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $4.98B | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $5.46B | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $5.42B | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $4.94B | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $4.22B | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $4.30B | Dec 17, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Oct 31, 2017 | $3.19B | Dec 20, 2017 |
| FY2017 | Oct 31, 2016 | $2.92B | Dec 20, 2017 |
| FY2017 | Oct 31, 2015 | $2.86B | Dec 20, 2017 |
| FY2016 | Oct 31, 2014 | $2.93B | Dec 19, 2016 |
| FY2015 | Oct 31, 2013 | $2.89B | Dec 21, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $850.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $614.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $1.06B | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $1.12B | Dec 17, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $876.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $833.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $1.36B | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $1.33B | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $1.08B | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $765.00M | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $711.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | ($394.00M) | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | $148.00M | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | $406.00M | Dec 18, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.01B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $919.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $882.00M | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $841.00M | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $811.00M | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $715.00M | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $688.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $624.00M | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | $507.00M | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | $425.00M | Dec 18, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.47B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $1.40B | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $1.31B | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $1.28B | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $1.20B | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $1.10B | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $1.16B | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $1.21B | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | $1.06B | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | $818.00M | Dec 18, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.41B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $1.05B | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $1.41B | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $1.14B | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $1.32B | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $1.02B | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $998.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $555.00M | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | $328.00M | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | $420.00M | Dec 18, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $128.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $154.00M | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $197.00M | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $185.00M | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $174.00M | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $117.00M | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $120.00M | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $132.00M | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | $72.00M | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | $91.00M | Dec 18, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $11.30B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $9.27B | Dec 17, 2025 |
| FY2024 | Oct 31, 2023 | $8.68B | Dec 17, 2024 |
| FY2023 | Oct 31, 2022 | $8.10B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $7.78B | Dec 15, 2022 |
| FY2021 | Oct 31, 2020 | $7.22B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $6.62B | Dec 17, 2020 |
| FY2019 | Oct 31, 2018 | $5.82B | Dec 18, 2019 |
| FY2018 | Oct 31, 2017 | $5.93B | Dec 18, 2018 |
| FY2017 | Oct 31, 2016 | $3.80B | Dec 20, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.42B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $4.16B | Dec 17, 2025 |
| FY2024 | Oct 31, 2023 | $4.03B | Dec 17, 2024 |
| FY2023 | Oct 31, 2022 | $3.94B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $4.00B | Dec 15, 2022 |
| FY2021 | Oct 31, 2020 | $3.92B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $3.62B | Dec 17, 2020 |
| FY2019 | Oct 31, 2018 | $3.39B | Dec 18, 2019 |
| FY2018 | Oct 31, 2017 | $3.62B | Dec 18, 2018 |
| FY2017 | Oct 31, 2016 | $2.28B | Dec 20, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.88B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $5.11B | Dec 17, 2025 |
| FY2024 | Oct 31, 2023 | $4.65B | Dec 17, 2024 |
| FY2023 | Oct 31, 2022 | $4.16B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $3.78B | Dec 15, 2022 |
| FY2021 | Oct 31, 2020 | $3.30B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $3.00B | Dec 17, 2020 |
| FY2019 | Oct 31, 2018 | $2.43B | Dec 18, 2019 |
| FY2018 | Oct 31, 2017 | $2.31B | Dec 18, 2018 |
| FY2017 | Oct 31, 2016 | $1.51B | Dec 20, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $3.42B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $2.39B | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $1.64B | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | $1.58B | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | $1.63B | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | $1.54B | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | $1.21B | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | $1.17B | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | $1.88B | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | $736.00M | Dec 18, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $7.08B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $6.23B | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | $5.61B | Dec 17, 2025 |
| FY2025 | Oct 31, 2022 | $4.55B | Dec 17, 2025 |
| FY2022 | Oct 31, 2021 | $3.43B | Dec 15, 2022 |
| FY2021 | Oct 31, 2020 | $2.54B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $1.91B | Dec 17, 2020 |
| FY2019 | Nov 1, 2018 | $1.29B | Dec 18, 2019 |
| FY2019 | Oct 31, 2018 | $1.21B | Dec 18, 2019 |
| FY2018 | Oct 31, 2017 | $1.04B | Dec 18, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.87B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $1.80B | Dec 17, 2025 |
| FY2024 | Oct 31, 2023 | $2.47B | Dec 17, 2024 |
| FY2023 | Oct 31, 2022 | $2.04B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $2.05B | Dec 15, 2022 |
| FY2021 | Oct 31, 2020 | $1.76B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $1.60B | Dec 17, 2020 |
| FY2019 | Oct 31, 2018 | $913.00M | Dec 18, 2019 |
| FY2018 | Oct 31, 2017 | $818.00M | Dec 18, 2018 |
| FY2018 | Oct 31, 2016 | $783.00M | Dec 18, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.53B | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | $1.79B | Dec 17, 2025 |
| FY2024 | Oct 31, 2023 | $1.79B | Dec 17, 2024 |
| FY2023 | Oct 31, 2022 | $1.79B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $1.79B | Dec 15, 2022 |
| FY2021 | Oct 31, 2020 | $1.79B | Dec 17, 2021 |
| FY2020 | Oct 31, 2019 | $1.79B | Dec 17, 2020 |
| FY2019 | Oct 31, 2018 | $1.29B | Dec 18, 2019 |
| FY2018 | Oct 31, 2017 | $2.04B | Dec 18, 2018 |
| FY2017 | Oct 31, 2016 | $1.09B | Dec 20, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 4 | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | 3 | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | 5 | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | 6 | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | 4 | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | 3 | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | 3 | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | 0 | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | 0 | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | 1 | Dec 18, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 4 | Dec 17, 2025 |
| FY2025 | Oct 31, 2024 | 3 | Dec 17, 2025 |
| FY2025 | Oct 31, 2023 | 5 | Dec 17, 2025 |
| FY2024 | Oct 31, 2022 | 6 | Dec 17, 2024 |
| FY2023 | Oct 31, 2021 | 4 | Dec 15, 2023 |
| FY2022 | Oct 31, 2020 | 3 | Dec 15, 2022 |
| FY2021 | Oct 31, 2019 | 3 | Dec 17, 2021 |
| FY2020 | Oct 31, 2018 | 0 | Dec 17, 2020 |
| FY2019 | Oct 31, 2017 | 0 | Dec 18, 2019 |
| FY2018 | Oct 31, 2016 | 1 | Dec 18, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Oct 31, 2015 | 170.00M | Dec 21, 2015 |
| FY2015 | Oct 31, 2014 | 167.00M | Dec 21, 2015 |